View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &
Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– MSD (tradename of Merck & Co., Inc., Rahway, N.J. USA) and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
March 21, 2023 |
Official notification to shareholders of matters to be brought to a vote (“Proxy”) |
DEF 14A |
Proxy Filings |
|
|
March 21, 2023 |
An annual report to security holders |
ARS |
Annual Filings |
|
|
March 10, 2023 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
|
March 7, 2023 |
F-6EF |
F-6EF |
Other |
|
|
March 7, 2023 |
S-3ASR |
S-3ASR |
Registration Statements |
|
|
March 7, 2023 |
Annual report which provides a comprehensive overview of the company for the past year |
10-K |
Annual Filings |
|
|
March 7, 2023 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
February 14, 2023 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
February 14, 2023 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
